Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial

Diabetic dyslipidaemia is a major risk factor for accelerated atherosclerosis. Glycaemic treatments that improve dyslipidaemia may help reduce the burden of atherosclerosis. This analysis investigated the effect of iGlarLixi [insulin glargine U100 (iGlar) and lixisenatide] versus iGlar on lipid prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgino, Francesco, Shaunik, Alka, Liu, Minzhi, Saremi, Aramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899526/
https://www.ncbi.nlm.nih.gov/pubmed/31423722
http://dx.doi.org/10.1111/dom.13857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899526/
https://www.ncbi.nlm.nih.gov/pubmed/31423722
http://dx.doi.org/10.1111/dom.13857

Ejemplares similares